Shots:
- Altimmune has reported 48wk. data from the P-IIb (IMPACT) trial assessing pemvidutide (1.2 or 1.8mg, SC, QW) vs PBO in 212 pts with MASH & fibrosis stages F2 or F3, with & without diabetes
- Pemvidutide (1.8mg) showed a reduction in triglycerides by 23.7%, total cholesterol by 15.4%, BMI by 3kg/m², waist circumference by 5.3cm, systolic/diastolic BP by 4/2.2 mmHg, while delivering sustained 7.5% weight loss with no plateau observed; data were presented at EASL’26
- Pemvidutide is being evaluated in the P-II (RECLAIM) trial for alcohol use disorder, with topline data expected in Q3’26, & the RESTORE trial in alcohol-associated liver disease, with enrollment completion anticipated in Q3’26, while the P-III (PERFORMA) trial in MASH is planned to begin in H2’26
Ref: Globenewswire | Image: Altimmune | Press Release
Related News: GSK Reports the P-III (B-Well 1 and B-Well 2) Trial Data on Bepirovirsen for Chronic Hepatitis B at EASL 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
